Health Topics

The IDC website currently focuses its resources on two health topics: HIV/AIDS and Maternal and Child Health. There are, however, many other significant health topics in global health that have implications for diagnostics in resource-limited settings. These include tuberculosis, malaria and neglected tropical diseases, among others.  Resources on important issues in diagnostics for infectious diseases and health topics other than HIV/AIDS and Maternal and Child Health can be found under Other Health Topics on this site.

Development and Evaluation


In order to guide developers in product design and development of diagnostic tests, in particular those for use at or near the point of patient care, standards are needed. The standards are a set of desired operational and technical specifications for diagnostic platforms being developed for use at various levels of the laboratory system in resource-limited settings. These standards can be summarized in a Target Product Profile (TPP) that provides a clear set of minimal and optimal standards for each platform, including the device, if any, and the assay. A TPP sets forth specifications for each test platform and is generally divided into three main sections: (i) intended use; (ii) technical performance; and (iii) operational characteristics.


Once diagnostic products are developed, it is essential for developers to have an in-depth understanding of the evaluation process for in vitro diagnostics (IVDs) in-country in order to facilitate introduction and uptake of their products. There are currently no uniform diagnostic quality standards to guide product selection in resource-limited settings. As a result, in-country evaluations are an essential part of the development process for new IVDs. Such evaluations generally take place in two stages: (i) clinical evaluations in controlled settings in-country that test, among other things, internal consistency (precision) as well as accuracy against an appropriate reference technology, and (ii) field evaluations in-country that introduce additional variables, including the use of the product by minimally-trained lay operators.

Resources associated with these areas include:

  • TPPs for a number of specific diagnostic assays – e.g. quantitative viral load assay for HIV/AIDs
  • Links to UNITAID landscape reports, which contain descriptions of pipeline technologies.
  • General principles on how to design and conduct diagnostic evaluations
  • Standardized/generic protocols for clinical evaluations
  • A network of accredited evaluation sites in-country for various IVDs
  • Publications of test performance, including systematic reviews

Policy and Implementation


The ultimate decision to introduce new diagnostic technologies in-country rests with the ministry of health. In-country policies must accommodate the new technologies and ministries often require guidance with respect to appropriate technology placement, impact and cost-effectiveness.


In order to achieve successful implementation and uptake of a diagnostic in-country, it is essential that developers understand the landscape and the tools to effectively coordinate these activities. A number of systems support diagnostic testing in-country. These include:

  • Supply chain
  • Human resources and training
  • Service delivery design
  • Service and maintenance
  • Quality assurance

Successful implementation of new diagnostic technologies requires that each of these systems functions well, but they are often weak or lacking in-country. For example, ineffective supply chain systems (forecasting, procurement and distribution) can lead to perennial consumable and reagent shortages. 

Shortages not only lead to costly emergency fixes, but also are detrimental to the quality of patient care. Some common diagnostic tests require not only test reagents, but also numerous associated consumables, collection supplies, and quality controls to come together at the same time to ensure a quality result.

In resource-limited settings, supply chain challenges include:

  • Remote locations – hours from major towns, poor road conditions, seasonally impassable
  • Limited infrastructure – limited electricity and access to communication
  • Paper-based recordkeeping
  • Human resources capacity

These problems are more pronounced when implementing point-of-care diagnostics, which require more devices/tests in more remote locations than centralized testing; for which it is more costly and complex to distribute reagents and consumables; and which requires procurement, forecasting and managing inventories of testing supplies at a greater number of sites.

Technology implementation challenges include managing each of these areas of weakness, including training, service/maintenance and piloting quality assurance systems. It also includes understanding and navigating the various key partners in-country, in addition to ministries of health.

Resources associated with these areas include:

  • Technology assessment and strategic placement tools
  • Models for impact assessment and cost-effectiveness
  • Sources of diagnostic and laboratory practice training
  • Quality Assurance/Quality Control materials and information on quality management of diagnostic laboratories
  • Toolkits (e.g. rapid syphilis test toolkit) and links to other toolkits
  • Links to publications on operations research


The purpose of regulation is to protect public health by assuring the safety, effectiveness, and quality of diagnostic tests while enabling timely access to beneficial new products. 

This website contains resources on a range of regulatory topics including:

Regulation of in-vitro diagnostic devices (IVDDs)

National and regional regulatory legislation and requirements

Global and regional harmonization initiatives 


  • Other
    Originally published on 28 October 2017


    This resource was developed by the IDC team to serve as a guide on the current state of the art diagnostics for ACDx fellows of 2017. 

  • Other
    Originally published on 26 October 2017

    The Point-of-Care Diagnostic Landscape for Sexually Transmitted Infections (STIs)

    Sexually transmitted infections (STIs) continue to be a significant global public health issue, with an estimated 357 million people becoming ill each year with one of 4 STIs: syphilis, Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Tri

  • Other
    Originally published on 21 October 2017

    Chikungunya Virus Diagnostics Landscape

    Chikungunya virus (CHIKV) fever is an arboviral infection transmitted primarily by Aedes mosquitoes, the same mosquitoes that transmit Zika virus (ZIKV) and dengue virus (DENV) fevers. Unlike ZIKV and DENV, CHIKV has not gotten much publicity. But, in recent years, it has reemerged as a significant global public health concern.

  • Other
    Originally published on 21 October 2017

    Zika Virus InfectionsDiagnostics Landscape

    Because of a recent and ongoing epidemic, Zika virus (ZIKV) infection is of worldwide concern. ZIKV infection has generally been considered an unimportant public health problem with only sporadic cases in humans reported in the literature until 2006.

  • Other
    Originally published on 21 October 2017

    Dengue Virus Infection Diagnostics Landscape

    Dengue, which is an arthropod-borne viral infection, is endemic to both tropical and sub-tropical regions of the world and is a global public health concern. While once considered an unimportant public health problem because mortality rates were low and epidemics infrequent, dengue virus (DENV) infection incidence rates have increased 30-fold in the past 50 years

  • Report
    Originally published on 20 September 2017

    Paris CD4 Workshop

    The International Diagnostics Centre (IDC) held a workshop with funders at IAS2017 in Paris to discuss the role of CD4 testing in country programs as they are scaling up viral load testing. This report is a summary of the discussions at the workshop.

  • Report
    Originally published on 19 July 2017

    Nairobi CD4 Workshop

    The International Diagnostics Centre (IDC) held the first of a series of regional workshops in Nairobi on May 18-19, 2017 to discuss the role of CD4 testing in country programs as they are scaling up viral load testing. Five countries from the East African Community (Burundi, Kenya, Rwanda, Tanzania and Uganda) participated in this workshop.

  • Report
    Originally published on 21 April 2017

    ASLM2016 CD4 Workshop Report

    In December 2016, the International Diagnostics Centre (IDC), the London School of Hygiene and Tropical Medicine (LSHTM) and the African Society of Laboratory Medicine (ASLM) convened a workshop comprised of key stakeholders and opinion leaders to address and clarify critical issues relating to the use of CD4 testing in the management of HIV.

  • Report
    Originally published on 23 August 2016

    UNITAID Diagnostics Technology and Market Landscape (4th Edition)

    The UNITAID Tuberculosis Diagnostics Technology and Market Landscape is published annually and is prepared as part of a broad and ongoing effort to understand the technology and market landscape for tu- berculosis (TB) diagnostics.

  • Report
    Originally published on 23 August 2016

    Malaria Diagnostics Technology and Market Landscape (3rd Edition)

    The 2016 Malaria diagnostics technology and market landscape is part of a broad and ongoing effort to understand the technology and market landscapes for malaria diagnostics. 


Contact us

The International Diagnostics Centre
London School of Hygiene & Tropical Medicine
Keppel St
United Kingdom
admin [at] idc-dx [dot] org